Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.
Nat Clin Pract Gastroenterol Hepatol
; 1(2): 90-7, 2004 Dec.
Article
en En
| MEDLINE
| ID: mdl-16265070
ABSTRACT
In the past decade, substantial advances have been made in the treatment of chronic hepatitis B. Approved treatments include interferon-alpha, the nucleoside analog inhibitor lamivudine, and the nucleotide analog inhibitor adefovir dipivoxil. This review provides insights into the benefits and limitations of lamivudine and adefovir dipivoxil for the treatment of chronic hepatitis B. Lamivudine and adefovir dipivoxil have similar antiviral efficacies. Lamivudine has negligible side effects but a high rate of drug resistance, whereas adefovir dipivoxil has a low rate of drug resistance but long-term use is associated with a small risk of nephrotoxicity. Several other nucleoside and nucleotide analogs are being evaluated in phase II/III clinical trials for hepatitis B.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores de la Transcriptasa Inversa
/
Hepatitis B
/
Nucleósidos
/
Nucleótidos
Límite:
Humans
Idioma:
En
Revista:
Nat Clin Pract Gastroenterol Hepatol
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2004
Tipo del documento:
Article
País de afiliación:
Estados Unidos